COULD THIS NEW NON-OPIOID COMPLETELY REPLACE FENTANYL? | EP 42

Discover the future of pain management on this episode of Atomic Anesthesia as we explore a major breakthrough: the FDA approval of suzetrigine, a first-in-class, nonopioid pain medication. Guided by cutting-edge research and expert editorial insight from Anesthesiology, we dig into how suzetrigine works—targeting the NaV1.8 sodium channel in peripheral nerves—and what this means for patients and providers facing acute pain. You’ll hear about the pivotal NAVIGATE clinical trials, real-world patient experiences, and the medication’s advantages over traditional opioids, including fewer side effects and no risk of addiction. Whether you’re a healthcare professional, patient, or someone passionate about medical innovation, join us to learn how suzetrigine is poised to reshape pain relief and help bridge the gap left by the opioid crisis.

References:

1. Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21. PMID: 40117446; PMCID: PMC12061372.
2. Rathmell JP, Clark JD, Eisenach JC. Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain. Anesthesiology. 2025 Jun 1;142(6):989-991. doi: 10.1097/ALN.0000000000005465. Epub 2025 May 13. PMID: 40358331.

💜 LIVE WEBINAR: Save your seat on our monthly, free webinars. Replays are sent to your inbox and you get access to all of our previous webinars.

[WEBINAR SIGN UP]

💜 FREE DOWNLOADS: Grab your copy of customized study plans & worksheets.

[SEE/NCE STUDY PLAN]

[RN ICU DRUG CHART]

💜 CONNECT: 📥 Email questions, comments or topic suggestions to Dr. Temmermand at hello@atomicanesthesia.com, follow us on social media, and sign up for our launch newsletter ⬇️

[NEWSLETTER SIGN-UP]

[INSTAGRAM] [TIKTOK] [YOUTUBE]